High-intensity statins (atorvastatin, rosuvastatin) are used in patients with high CV risk as they lower LDL-C by 4063% and significantly reduce the incidence of major cerebral and coronary complications (190)
Analysis of commercial claims data covering approximately 50 million insured lives found GLP-1 users experienced: 44% fewer major cardiovascular-related hospitalizations 69% improvement in medical spend growth among diabetes-related GLP-1 users over 30 months 37% improvement in medical spend growth among weight-loss GLP-1 users over 18 months Researchers have also observed positive trends related to inflammatory conditions, cardiovascular disease, and other chronic health concerns
You can always adjust upward if you feel comfortable
For patients seeking deeper personalization, the Precision Peptide Genetic Test ($298) identifies how your genetic variants in GIPR and FTO, and MC4R pathways influence your response to therapy, helping your healthcare provider select the most effective compound and delivery method for your biology
Enhanced glucose control for preventing and treating diabetic neuropathy
In SURMOUNT-1, 72 weeks of tirzepatide induced mean WL of 1622.5% in people without diabetes compared to 2.4% with placebo, with no sign of the weight plateauing, suggesting that there may be further WL with long-term use [46]